| Title : MK-431 (Merck) - Deacon_2005_Curr.Opin.Investig.Drugs_6_419 |
| Author(s) : Deacon CF |
| Ref : Curr Opin Investig Drugs , 6 :419 , 2005 |
|
Abstract :
Merck & Co is developing MK-431, the lead from a series of dipeptidyl peptidase IV inhibitors that enhance endogenous glucagon-like peptide-1 levels, for the potential treatment of type 2 diabetes. Phase III studies were initiated in the second quarter of 2004. |
| PubMedSearch : Deacon_2005_Curr.Opin.Investig.Drugs_6_419 |
| PubMedID: 15898349 |
Deacon CF (2005)
MK-431 (Merck)
Curr Opin Investig Drugs
6 :419
Deacon CF (2005)
Curr Opin Investig Drugs
6 :419